@article {10.3844/ajvsp.2016.1.7,
article_type = {journal},
title = {The Practical Consideration of Poliovirus as an Oncolytic Virotherapy},
author = {Denniston, Elizabeth and Crewdson, Hannah and Rucinsky, Nicole and Stegman, Andrew and Remenar, Diana and Moio, Katherine and Clark, Brianne and Higginbotham, Alexandra and Keffer, Ross and Brammer, Sarah and Horzempa, Joseph},
volume = {5},
number = {1},
year = {2016},
month = {Mar},
pages = {1-7},
doi = {10.3844/ajvsp.2016.1.7},
url = {https://thescipub.com/abstract/ajvsp.2016.1.7},
abstract = {The inauguration of novel treatment strategies into the clinical setting faces a number of hurdles. In addition to treatment efficacy and safety, acceptance by doctors and patients is paramount to the success of novel therapies. Although viruses are the cause of numerous infectious diseases, these acellular entities have been harnessed over the years to benefit mankind. Recently, a recombinant Poliovirus-Rhinovirus Chimera (PVSRIPO) has shown promise for the treatment of glioblastoma in clinical trials as well as other cancer types in animal models. In this literature review, we discuss the use of PVSRIPO as an oncolytic virotherapy. In addition to being a potential treatment for glioblastoma, this recombinant virus could possibly be used against other cancers because many tumor cells express the PVSRIPO receptor antigens (CD155) and have a limited ability to control viral replication. Moreover, virus-induced immune responses contribute to the efficacy of PVSRIPO. Given the current trajectory of this experimental therapy, the possibility exists that PVSRIPO will soon be a viable treatment option for various cancer types. While many healthcare providers and cancer patients likely welcome this new viral based treatment, history has taught us that some may be skeptical and avoid its use because of the viral composition of this therapy.},
journal = {Current Research in Virology},
publisher = {Science Publications}
}